NRG Oncology trial results show favorable bowel health related quality of life outcomes for localized immediate risk prostate cancer treated with stereotactic body radiation therapy – Results published
Peer-Reviewed Publication
Updates every hour. Last Updated: 25-Oct-2026 04:16 ET (25-Oct-2026 08:16 GMT/UTC)
PHILADELPHIA, PA – Results of the NRG Oncology NRG-GU005 clinical study comparing stereotactic body radiation therapy (SBRT) to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for patients with localized intermediate risk prostate cancer indicate that the use of SBRT improved bowel health related quality of life (HRQOL) in this patient population. There was no significant improvement for SBRT seen for the other primary objectives including urinary HRQOL and disease-free survival. These results are now published in the Journal of the American Medical Association (JAMA) following the presentation during the Plenary Session of the 2025 American Society for Radiation Oncology Annual Meeting in San Francisco, California.
Researchers at Binghamton University, State University of New York have been awarded a $3.3 million grant from the National Institutes of Health to study drug transfer through human breast milk.
Exposure during pregnancy to a common type of pesticide was not linked to autism-related traits in children, according to a new study funded by the National Institutes of Health’s (NIH) Environmental influences on Child Health Outcomes (ECHO) Program.
The Patient-Centered Outcomes Research Institute (PCORI) announced funding for new patient-centered comparative clinical effectiveness research (CER) and related projects to inform clinical practice. The projects span emergency, hospital and outpatient care and address a range of health concerns including cancer, cardiovascular disease, mental and behavioral health, women’s health, pediatric care, rare diseases and chronic disease management.